Biosimilars: Some Patient And Prescriber Groups Appear To Warm Up To Arbitrary Suffixes

 
• By Michael Cipriano

Patient and prescriber groups were largely opposed to suffixes for the nonproprietary names of biological products being devoid of meaning when the US FDA first published its nomenclature policy, although a few of these groups may be signaling less of a worry than they once had. 

The US FDA has approved 20 biosimilars, all but one with an arbitrary suffix. Some patient and prescriber groups are now warming up to the nomencature.

More from Biosimilars

More from Biosimilars & Generics